Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial ...
Gyre Therapeutics (GYRE) announced its agreement to acquire Cullgen, a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader ...
Hosted on MSN
Key North Atlantic current is on the brink of collapse - plunging us into a 'Little Ice Age'
A key ocean current in the North Atlantic Ocean is weakening to the point of total collapse due to climate change, a new study warns. Scientists say the North Atlantic Subpolar Gyre – a massive system ...
A subpolar gyre is a large-scale ocean current system located at high latitudes created by a persistent region of low atmospheric pressure. These gyres circulate water in a cyclonic direction – ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems ...
Gyre Therapeutics, Inc. (GYRE) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.02 per share a year ago.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results